Medical Supplies

100 South Main Street, Suite 300
18901 Doylestown, PA
USA

Phone: (+1-267)8801595
Fax: (+1-267)8801596
http://www.quantrx.com
rberlie@quantrx.com

Company Profile

About us

QuantRx Biomedical Corporation (OTCBB: QTXB) is an emerging leader in the development of products for advanced diagnosis of serious disease and health conditions. With synergistic expertise in the discovery of diagnostic platforms and the commercialization of products for use by medical professionals, institutions or consumers,
QuantRx is focused on providing more accurate, reliable and faster diagnoses that result in improved patient care.

The QuantRx strategy is one of sustained growth and targets significant market opportunities estimated to be in excess of $4 billion worldwide.

QuantRx has corporate offices in Doylestown, Pennsylvania, and its research and development center in Portland, Oregon. The Company holds a majority position in FluoroPharma, Inc., a Boston-based molecular imaging company, and a significant position in Genomics USA, Inc., a Chicago-based developer of microarray technology for DNA testing.

As it looks to the future, QuantRx is committed to continually deliver value to its customers, partners, and shareholders through innovative advanced medical diagnostics and preeminent business practices.

Product Information
03.01.14 Rapid tests - clinical chemistry

03.02.15 Rapid tests - Immunochemistry
Lateral Flow Diagnostic Devices

QuantRx produces an array of innovative point-of-care testing products based on the Company’s core intellectual property.

Lateral flow tests rapidly provide medical information directly to healthcare professionals, patients and consumers.

With its proprietary technology, QuantRx developed RapidSense, the only one-step positive-read lateral flow test on the market. The unique characteristics of Rapid-Sense technology make it ideal for testing both urine and oral fluids.

It can be applied to products for various single or multiple test platforms for drugs of abuse, women’s health concerns such as pregnancy, fertility, ovulation and menopause as well as HIV and other sexually transmitted diseases.

Patented QuantRx technology also is the basis of the QuantRx OralSense oral fluid collection device specifically designed for rapid lateral flow tests. These tests quickly provide medical information directly to the healthcare professional or patient, and law enforcement personnel as well as schools, employers, athletic organizations and others for which regular drug screening is increasingly standard.

According to Kalorama Information, market growth is driven by several factors, including the following:

The increasing decentralization of medicine, where testing is moving away from hospitals and doctors’ offices to off-site testing facilities, pharmacies and other retail sites, as well as into the individual’s home.
Their dramatic benefits in the diagnostic process because they reduce time spent awaiting test results, often critical when prompt treatment is indicated.

They are easy to use, allowing at-home use and requiring less training for technicians when used in a healthcare environment.
As part of its strategy to develop Original Equipment Manufacturer (OEM) relationships, QuantRx partners with companies that are interested in exploring new and existing test platforms.